BVS
Bioventus Inc.
BVS has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over BVS overall, supported by stronger fundamentals.
BVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
BVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $10.86 | — |
| Current | 14x | $10.86 | — |
| Cheap | 18x | $14.37 | +32% |
| Fair | 26x | $21.13 | +95% |
| Expensive | 69x | $54.91 | +406% |
Historical ranges are pointers, not guarantees.
BVS has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BVS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for BVS, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BVS on the outlook, with more favorable valuation expectations.
BVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +1.6% |
| Q3 2026 | $0.80 | +627% |
| Q2 2026 | $0.77 | +$0.78 |
| Q1 2026 | $0.41 | +$0.90 |
| Q4 2025 | $0.33 | +$0.85 |
| Q3 2025 | $0.11 | +$0.69 |
| Q2 2025 | -$0.01 | +$0.62 |
| Q1 2025 | -$0.49 | -$0.17 |
| Q4 2024 | -$0.52 | +$1.97 |
BVS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $142.4M | +2.7% |
| Q2 2026 | $153.2M | +3.8% |
| Q1 2026 | $132.1M | +6.6% |
| Q4 2025 | $157.9M | +2.8% |
| Q3 2025 | $138.7M | -0.2% |
| Q2 2025 | $147.7M | -2.4% |
| Q1 2025 | $123.9M | -4.3% |
| Q4 2024 | $153.6M | +13% |
BVS's revenue grew through 2024 and has held roughly level since: $142M last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | -1.3 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | 6.4% | +2.4 points |
| Q4 2025 | 12% | +7.1 points |
| Q3 2025 | 8.1% | +5.2 points |
| Q2 2025 | 12% | +32 points |
| Q1 2025 | 3.9% | -0.2 points |
| Q4 2024 | 5.2% | +4.3 points |
BVS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.3M | -31% |
| Q2 2026 | $18.9M | -25% |
| Q1 2026 | $8.4M | +$28.5M |
| Q4 2025 | $37.4M | +99% |
| Q3 2025 | $29.6M | +189% |
| Q2 2025 | $25.3M | +67% |
| Q1 2025 | -$20.2M | -$13.9M |
| Q4 2024 | $18.7M | +87% |
BVS generated $85M in free cash flow over the past year, up 59% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BVS on cash flow, with more consistent year-over-year improvement.
BVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +1.7M shares |
| 1 year | +5.3% | +3.7M shares |
| 3 years | +15% | +9.7M shares |
| 5 years | +73% | +30.7M shares |
| Available history | +30% | +16.9M shares |
BVS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 4.9x | High |
| Q1 2025 | 20.2x | High |
| Q4 2024 | 18.0x | High |
BVS's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BVS on leverage, with a lower net debt burden relative to earnings.
BVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
BVS's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BVS PE vs Healthcare Sector
| Metric | BVS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 2 | 35 | 33 pts below |
BVS is trading at 14x earnings, a 48% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over BVS on valuation relative to its sector.
BVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 16% below |
| 20 week MA | $13.0 | 16% below |
| 50 week MA | $10.4 | 4.4% above |
| 100 week MA | $9.16 | 19% above |
| 200 week MA | $7.20 | 51% above |
BVS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 51% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BVS on trend strength, trading above more of its moving averages.
BVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.2 | $14.0 | -19% |
| 2022 | $14.0 | $2.54 | -82% |
| 2023 | $2.54 | $5.27 | +107% |
| 2024 | $5.27 | $10.6 | +102% |
| 2025 | $10.6 | $7.46 | -30% |
| 2026 YTD | $7.46 | $10.9 | +46% |
BVS's yearly returns have swung widely, from +107% in 2023 to −82% in 2022. It's up 46% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BVS on returns for 2026, with the stronger performance.